Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Arch. cardiol. Méx ; 90(supl.1): 19-25, may. 2020.
Article in Spanish | LILACS | ID: biblio-1152838

ABSTRACT

Resumen La pandemia por COVID-19 ha tenido muy importantes repercusiones negativas, sanitarias, psicológicas, sociales y económicas para las personas, las familias, las comunidades, los países y para las para la humanidad en general. La interrelación con la edad y la presencia de enfermedades crónicas no trasmisibles (hipertensión, diabetes, obesidad, tabaquismo) parece ir mas lejos que lo que explicaría la prevalencia y distribución de ambas. Los medicamentos que actúan sobre el sistema renina-angiotensina-aldosterona, son pilares básicos en el manejo de estas enfermedades. Se sabe de tiempo atrás que estos fármacos aumentan en forma significativa la expresión en el tejido pulmonar de receptores para la enzima de conversión de angiotensina de tipo 2. Este hecho junto con el conocimiento de que la vía de entrada del virus a la célula es precisamente el receptor de ECA-2, inició una hipótesis, basada en evidencia de muy baja calidad, que rápidamente se generalizó en los medios de comunicación, de que el empleo de estos medicamentos podría ser negativo y que deberían suspenderse. La respuesta de prácticamente todas las sociedades científicas fue casi inmediata, con la indicación precisa de que no debería suspenderse el tratamiento con estos fármacos, puesto que la evidencia de su utilidad está basada en una evidencia muy sólida y de gran calidad. Casi simultáneamente también apareció la hipótesis, también basada en evidencia muy preliminar, de que estos medicamentos no solo resultan dañinos sino que son benéficos, tampoco se aceptan todavía como agentes para la prevención o tratamiento de esta enfermedad o sus complicaciones. La presente revisión relata los conocimientos actuales sobre la relación entre COVID-19 y SRAA.


Abstract The COVID-19 pandemic has had major negative health, psychological, social and economic repercussions for individuals, families, communities, countries and for humanity in general. The interrelation with age and the presence of chronic non-communicable diseases (hypertension, diabetes, obesity, smoking) seems to go further than what would be explained by the prevalence and distribution of both. The drugs that act on the renin-angiotensin-aldosterone system are in many cases the backbone for the management of these diseases, it has been known for a long time that these drugs significantly increase the expression of receptors for angiotensin conversion enzyme type 2 in the lung tissue. This fact, together with the knowledge that the route of entry of the virus into the cell is precisely the ACE-2 receptor, initiated a hypothesis, based on very low-quality evidence, which quickly became generalized in the media, that the use of these drugs could be negative and that they should be interrupted immediately. The response of practically all Scientific Societies was almost immediate, with the precise indication that treatment with these drugs should not be discontinued, since the evidence of their usefulness is based on very solid and high-quality evidence. Simultaneously, a different hypothesis also appeared, also based on very preliminary evidence, that these drugs are not only harmful but also beneficial, however these medicaments are not yet accepted as agents for the prevention or treatment of this disease or its complications. This review reports current knowledge on the relationship between COVID-19 and SRAA.


Subject(s)
Humans , Animals , Pneumonia, Viral/virology , Renin-Angiotensin System/physiology , Coronavirus Infections/virology , Pneumonia, Viral/drug therapy , Renin-Angiotensin System/drug effects , Risk Factors , Coronavirus Infections/drug therapy , Coronavirus Infections/epidemiology , Peptidyl-Dipeptidase A/metabolism , Drug-Related Side Effects and Adverse Reactions/epidemiology , Pandemics , Angiotensin-Converting Enzyme 2 , COVID-19
2.
Clinical Medicine of China ; (12): 708-710, 2013.
Article in Chinese | WPRIM | ID: wpr-434757

ABSTRACT

Objective To investigate the relationship of serum angiotensin converting enzyme (ACE) level and primary hypertension target organ damage.Methods According to target organ damage,essential hypertension patients were divided into 3 groups:primary hypertension with coronary artery disease,primary hypertension with cerebral infarction and primary hypertension with kidney injury.There were 60 subjects in each complication group.There were 60 healthy adults in the normal control group.Serum ACE level was detected and compare among the 4 groups.Results Serum ACE level in normal control group was (21.36 ± 6.86) U/L,while that in primary hypertension with coronary artery disease,primary hypertension with cerebral infarction and primary hypertension with kidney injury were (36.09 ±4.87) U/L,(39.15 ±7.03) U/L and (28.34 ±7.23) U/L respectively.Serum ACE level was higher in each complication group than in normal control group (F =343.997,P < 0.01).In the complication groups,serum ACE level was the lowest in the group of primary hypertension with kidney injury.Conclusion High active ACE is associated with target organ damage in primary hypertension,especially kidney injury.

SELECTION OF CITATIONS
SEARCH DETAIL